Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genzyme licenses hernia repair product to CR Bard

Executive Summary

Genzyme licensed CR Bard (vascular, urological, cancer, and surgical devices) manufacturing and marketing rights to its Sepramesh IP hernia repair line along with rights to use the Sepra bioresorbable coating technology in developing new products for hernia repair.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Product Purchase

Related Companies

Advertisement
UsernamePublicRestriction

Register